Effect of a novel inducible nitric oxide synthase inhibitor, FR260330, in prevention of renal ischemia/reperfusion injury in vervet monkeys

Transplantation

Volumn 81, Issue 4, 2006, Pages 627-631

  Qi, Shijie ^a   Xu, Dasheng ^a   Ma, Anlun ^a   Zhang, Xiaochun ^a   Chida, Noboru ^b   Sudo, Yuji ^b   Tamura, Kouichi ^b   Daloze, Pierre ^a   Chen, Huifang ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

FR260330; iNOS inhibitor; Ischemia reperfusion injury; Kidney

Indexed keywords

FR 260330; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFECT; EVALUATION; KIDNEY FUNCTION; KIDNEY ISCHEMIA; MALE; MONKEY; NEPHRECTOMY; NONHUMAN; PARAMETER; PRIORITY JOURNAL; REPERFUSION INJURY; SURVIVAL;

ANIMALS; CERCOPITHECUS AETHIOPS; ENZYME INHIBITORS; KIDNEY; MALE; MODELS, ANIMAL; NITRIC OXIDE SYNTHASE TYPE II; PIPERIDINES; REPERFUSION INJURY;

EID: 33644633072     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000199282.05021.0c     Document Type: Article

References (29)

1. Walaszewski J, Rowinski W, Pacholczyk M, et al. Multiple risk factor analysis of delayed graft function (ATN) after cadaveric transplantation: positive effect of lidocaine donor pretreatment. Transplant Proc 1991; 23(5): 2475.
2. Koning OH, van Bockel JH, van der Woude EJ, et al. Risk factors for delayed graft function in University of Wisconsin solution preserved kidneys from multiorgan donors. European Multicenter Study Group on Organ Preservation. Transplant Proc 1995; 27(1): 752.
3. Corman J, Moukarzel M, Guttmann R, et al. Quebec Metro-Transplantation Multicenter Study on delayed graft function in kidney transplantation. Transplant Proc 1988; 20(1 suppl 1): 428.
4. Michael HJ, Francos GC, Burke JF, et al. A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation 1989; 48(5): 805.
5. Feldman HI, Burns JE, Both DA, et al. Race and delayed kidney allograft function. Nephrol Dial Transplant 1998; 13: 704.
6. Yokoyama I, Uchida K, Kobayashi T, et al. Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation Clin Transplant 1994; 8(2 Pt 1): 101.
7. Almond PS, Troppmann C, Escobar F, et al. Economic impact of delayed graft function Transplant Proc 1991; 23(1 Pt 2):1304.
8. Rocenthal JT, Danovitch GM, Wilkinson A, Ettenger RB. The high cost of delayed graft function in cadaveric renal transplantation. Transplantation 1991; 51(5): 1115.
9. Stallone G, Di Palolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Nephrol 2004; 15(1): 228.
10. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil of azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results in three years. Transplantation 2003; 75(12): 2048.
11. Matas AJ, Gillingham KJ, Humar A, et al. Immunologic and nonimmunologic factors: Different risks for cadaver and living donor transplantation. Transplantation 2000; 69: 54.
12. Tillius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
13. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spoual and living unrelated donors. N Engl J Med 1995; 333: 333.
14. Ke B, Shen XD, Gao F, et al. The CD154-CD40 T-cell co-stimulation pathway in liver ischemia and reperfusion inflammatory responses. Transplantation 2005; 79: 1078.
15. Pratschke J, Wilhelm MJ, Laskowski I, et al. Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol 2001; 12: 2474.
16. Moncada S, Palmer R, Higgs E. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109.
17. Russell ME, Wallace AF, Wyner LR, et al. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation 1995; 92: 457.
18. Akyurek LM, Fellstrom BC, Yan ZQ, et al. Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic allografts. Am J Pathol 1996; 149: 1981.
19. Wever R, Van Dam T Van Rijn H et al. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 1997; 237: 340.
20. Vos I, Joles J, Schurink M, et al. Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointerstitial injury in renal allograft rejection. Eur J Pharmacol 2000; 391: 31.
21. Goto M, Yamaguchi Y, Ichiguchi O, et al. Phenotype and localization of macrophages expressing inducible nitric oxide synthase in rat hepatic allograft rejection. Transplantation 1997; 64: 303.
22. Chida N, Hirasawa Y, Ohkawa T, et al. Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor. Eur J Pharmacol 2005; 509: 71.
23. Ouyang J, Xu D, Zhang X, et al. Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejection. Transplantation 2005; 79: 1386.
24. Xie Q, Cho H, Calaycay J, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophage. Science 1992; 256: 225.
25. Dattilo J, Dattilo M, Spratt J, et al. Inducible nitric oxide synthase expression in human vein grafts. Am J Surg 1997; 174: 177.
26. Furusu A, Miyazaki M, Abc K, et al. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int 1998; 53: 1760.
27. Salkowski C, Detore G, McNally R, van Rooijen N Vogel S. Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo: the roles of macrophage, endogenous IFN-gamma, and TNF receptor-1-mediated signaling. J Immunol 1997; 158: 905.
28. Blasko E, Glaser C, Devlin J, et al. Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J Biol Chem 2002; 277: 295.
29. Prado R, Watson BD, Kuluz J, Dietrich WD. Endothelium-derived nitric oxide synthase inhibition. Effects on cerebral blood flow, pial artery diameter, and vascular morphology in rats. Stroke 1992; 23: 1118.